Prospective Phase I Trial of Concurrent Full Dose Gemcitabine/Nab-paclitaxel and Ablative Radiation Therapy for Borderline and Locally Advanced Pancreatic Cancer

被引：0
|
作者：
Kim, H. [1 ]
Olsen, J. R. [2 ]
Wang-Gillam, A. [3 ]
Green, O. L. [1 ]
Fields, R. C. [4 ]
Hammill, C. [4 ]
Strasberg, S. [4 ]
Doyle, M. B. [4 ]
Hawkins, W. [4 ]
Suresh, R. [5 ]
Tan, B. [5 ]
Pedersen, K. [5 ]
Henke, L. E. [1 ]
DeWees, T. A. [6 ]
Chapman, W. [4 ]
Parikh, P. J. [7 ]
Roach, M. C., Jr. [1 ]
机构：
[1] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA
[2] Washington Univ, Sch Med, St Louis, CO USA
[3] Washington Univ, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA
[5] Washington Univ, Sch Med, Dept Med, Div Hematol Oncol, St Louis, MO 63110 USA
[6] Mayo Clin, Dept Biomed Informat, Scottsdale, AZ USA
[7] Henry Ford Hlth Syst, Dept Radiat Oncol, Detroit, MI USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期
关键词：
D O I：
10.1016/j.ijrobp.2019.06.283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1203
引用
收藏
页码：S209 / S210
页数：2
相关论文
共 50 条
  • [1] Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer
    Takahashi, Hidenori
    Akita, Hirofumi
    Ioka, Tatsuya
    Wada, Hiroshi
    Tomokoni, Akira
    Asukai, Kei
    Ohue, Masayuki
    Yano, Masahiko
    Ishikawa, Osamu
    PANCREAS, 2018, 47 (09) : 1135 - 1141
  • [2] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Tsujimoto, Akiko
    Sudo, Kentaro
    Nakamura, Kazuyoshi
    Kita, Emiri
    Hara, Ryusuke
    Takayama, Wataru
    Ishii, Hiroshi
    Yamaguchi, Taketo
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [3] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
    Akiko Tsujimoto
    Kentaro Sudo
    Kazuyoshi Nakamura
    Emiri Kita
    Ryusuke Hara
    Wataru Takayama
    Hiroshi Ishii
    Taketo Yamaguchi
    Scientific Reports, 9
  • [4] Prospective phase I study of nab-paclitaxel plus gemcitabine with concurrent MR-guided IMRT in patients with locally advanced or borderline resectable pancreatic cancer.
    Olsen, Jeffrey R.
    Parikh, Parag J.
    DeWees, Todd A.
    Olsen, Lindsey
    Hawkins, William G.
    Strasberg, Steven M.
    Lim, Kian-Huat
    Singh, Preet Paul
    Suresh, Rama
    Tan, Benjamin R.
    Ratner, Lee
    Fields, Ryan C.
    Amin, Manik A.
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] Phase I trial of enzalutamide in combination with gemcitabine and nab-paclitaxel in the management of advanced pancreatic cancer
    Kommalapati, A.
    Kim, R.
    Harsha, T. Sri
    Bertels, B.
    Wapinsky, G.
    Burke, N.
    Neuger, A.
    Springett, G.
    Almhanna, K.
    Mahipal, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E135 - E135
  • [6] Phase II LAPACT Trial of Nab-Paclitaxel Plus Gemcitabine for Patients With Locally Advanced Pancreatic Cancer
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 9 - 10
  • [7] Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: A phase I trial
    Safran, H
    Dipetrillo, T
    Iannitti, D
    Quirk, D
    Akerman, P
    Cruff, D
    Cioffi, W
    Shah, S
    Ramdin, N
    Rich, T
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (01): : 137 - 141
  • [8] Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer
    Okada, Ken-Ichi
    Hirono, Seiko
    Kawai, Manabu
    Miyazawa, Motoki
    Shimizu, Atsushi
    Kitahata, Yuji
    Ueno, Masaki
    Hayami, Shinya
    Yamaue, Hiroki
    ANTICANCER RESEARCH, 2017, 37 (02) : 853 - 858
  • [9] A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer
    Shabason, Jacob E.
    Chen, Jerry
    Apisarnthanarax, Smith
    Damjanov, Nevena
    Giantonio, Bruce
    Loaiza-Bonilla, Arturo
    O'Dwyer, Peter J.
    O'Hara, Mark
    Reiss, Kim A.
    Teitelbaum, Ursina
    Wissel, Paul
    Drebin, Jeffrey A.
    Vollmer, Charles
    Kochman, Michael
    Mick, Rosemarie
    Vergara, Norge
    Jhala, Nirag
    Doucette, Abigail
    Lukens, John N.
    Plastaras, John P.
    Metz, James M.
    Ben-Josef, Edgar
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (03) : 609 - 614
  • [10] A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer
    Jacob E. Shabason
    Jerry Chen
    Smith Apisarnthanarax
    Nevena Damjanov
    Bruce Giantonio
    Arturo Loaiza-Bonilla
    Peter J. O’Dwyer
    Mark O’Hara
    Kim A. Reiss
    Ursina Teitelbaum
    Paul Wissel
    Jeffrey A. Drebin
    Charles Vollmer
    Michael Kochman
    Rosemarie Mick
    Norge Vergara
    Nirag Jhala
    Abigail Doucette
    John N. Lukens
    John P. Plastaras
    James M. Metz
    Edgar Ben-Josef
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 609 - 614
12345